Researchers continue to excited about this new drug, a innovative dual agonist showing promising outcomes in initial trials for size reduction . It functions by targeting several pathways : GLP-1 and GIP, that , when stimulated, support regulate hunger and enhance energy expenditure . Initial observations suggest substantial body management and pot